Trial site
Buenos Aires
Buenos Aires, 1417, ArgentinaNot linked to an institution yet
- 12running trials
- 4closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 24 trials
- Phase 41 trial
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Completed4 trials
- Enrolling by invitation2 trials
- Lead sponsor
- Sanofi15 trials
- Bioverativ, a Sanofi company1 trial
Running trials
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569· Phase 2· Sanofi· Source
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931· Phase 3· Sanofi· Source
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423· Phase 4· Sanofi· Source
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222· Phase 3· Sanofi· Source
Enrolling by invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099· Phase 3· Sanofi· Source
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891· Phase 3· Sanofi· Source
Enrolling by invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315· Phase 3· Sanofi· Source
Active, not recruiting
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· Phase 2· Sanofi· Source
Active, not recruiting
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166· Phase 3· Sanofi· Source
Active, not recruiting
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575· Phase 3· Bioverativ, a Sanofi company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error